Helpful resources to support your practice

Downloadable Resources

VASCEPA Efficacy Data

VASCEPA Efficacy Data

Key data and safety information for VASCEPA

Download

VASCEPA Secondary Prevention Data

VASCEPA Secondary Prevention Data

First, subsequent, and total CV events data for statin-treated patients on VASCEPA

Download

State DAW Requirements

State DAW Requirements

Reference sheet for any state-specific requirements to dispense branded VASCEPA

Download

ICD-10 Coding Flashcard

ICD-10 Coding Flashcard

Information to help complete payer forms for VASCEPA

Download

Formulary Status for Select Plans

Formulary Status for Select Plans

Information on which coverage plans exclusively carry VASCEPA

Download

BlinkRx Troubleshooting Guide

BlinkRx Troubleshooting Guide

If you're having trouble finding BlinkRx in the EMR, this guide will take you step by step through the process


Download


VASCEPA Savings Card

VASCEPA Savings Card

Learn how eligible patients can sign up to save on VASCEPA with the universal VASCEPA Savings Card.*

Terms and conditions apply. See https://vascepa.copaysavingsprogram.com for eligibility criteria and other details.

Twice as many patients can pay $9 or less for branded VASCEPA compared to generic icosapent ethyl.


Peer-to-Peer Educational Video

Watch Dr. Kohli debunk a common misconception regarding LDL-C and Persistent Cardiovascular Risk (P-CVR)

Learn more about the Important Safety Information
See the groundbreaking results from the VASCEPA CV Outcomes Trial (REDUCE-IT®)View now

Virtual Speaker Programs

Join your peers at convenient times as they discuss how your statin-treated patients can benefit from VASCEPA

Register now

On-Demand Expert Perspectives

Expert Perspective: Dr. Canto

Dr. Canto headshot

Watch Dr. John Canto highlight the urgency to treat P-CVR and the role of VASCEPA

Register and watch

Expert Perspective: Dr. Kohli

Dr. Kohli headshot

Watch Dr. Payal Kohli speak at AHA 2020 about the benefits of VASCEPA in elevating the standard of cardiovascular care

Register and watch

Expert Perspective: Dr. Karalis

Dr. Karalis headshot

Watch Dr. Dean Karalis speak at NLA 2020 about reducing CV risk with VASCEPA

Register and watch

This site uses cookies to give you the best possible experience. By browsing our website, you agree to our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit the Privacy Policy page.

IMPORTANT SAFETY INFORMATION

VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components

VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter

It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur

INDICATIONS AND LIMITATIONS OF USE

VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease

VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin

Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)

Common adverse reactions in the hypertriglyceridemia trials (incidence ≥1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)

Adverse Events, Product Complaints, or Special Situations may be reported by contacting AmarinConnect at 1-855-VASCEPA, emailing [email protected], or calling the FDA at 1-800-FDA-1088

Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding

Please see full Prescribing Information for more information on VASCEPA.

AHA=American Heart Association; CV=cardiovascular; DAW=dispense as written; EMR=electronic medical record; LDL-C=low-density lipoprotein cholesterol; NLA=National Lipid Association.
*Universal Pharmacy Card (UPC) may be applied for any eligible patient by entering all 4 codes into the notes section of an e-prescription.
Data based on analysis of DRG formulary data and Symphony claims data of patients’ final out-of-pocket cost, with eligible, commercially insured patients using the VASCEPA Savings Card. Data on file.